Table 1.
Flow cytometry stainings per panel.
| Panel | Specificity | Conjugation | Vendor |
|---|---|---|---|
| Memory | EGFR (Cetuximab biosimilar) | Biotin | R&D systems, FAB9577B |
| Streptavidin | PE | Biolegend®, 405204 | |
| CD3 | APC | BD Pharmingen™, 555335 | |
| CD4 | FITC | BD Pharmingen™, 555346 | |
| CD8 | APC-Cy7 | BD Pharmingen™, 557834 | |
| CD197 (CCR7) | PE-CF594 | BD Pharmingen™, 562381 | |
| CD45RA | PE-Cy7 | BD Pharmingen™, 560675 | |
| DNA | 7AAD | BD Pharmingen™, 51–68981E | |
| Exhaustion | Human FAB | PE | R&D systems, FAB9577B |
| CD3 | ECD | Beckman Coulter, A07748 | |
| CD4 | AF700 | BD Pharmingen™, 557922 | |
| CD8 | APC-Cy7 | BD Pharmingen™, 557834 | |
| CD279 (PD-1) | FITC | BD Pharmingen™, 557860 | |
| CD223 (LAG-3) | BV650 | Biolegend®, 369316 | |
| CD366 (TIM-3) | BV785 | Biolegend®, 345032 | |
| LIVE/DEAD™ Fixable Aqua | Invitrogen, L34957 | ||
| Trogocytosis | Human FAB | RPE | Jackson Immunoresearch, 109–116- 097 |
| CD3 | ECD | Beckman Coulter, A07748 | |
| CD4 | AF700 | BD Pharmingen™, 557922 | |
| CD8 | APC-Cy7 | BD Pharmingen™, 557834 | |
| MSLN | APC | R&D systems, FAB32652A | |
| LIVE/DEAD™ Fixable Aqua | 405 nm | Invitrogen, L34957 | |
| Functional trogocytosis | EGFR (Cetuximab biosimilar) | Biotin | R&D systems, FAB9577B |
| Streptavidin | PE | R&D systems, FAB9577B | |
| CD3 | PE-Cy7 | BD Pharmingen™, 557851 | |
| CD4 | AF700 | BD Pharmingen™, 557922 | |
| CD8 | APC-Cy7 | BD Pharmingen™, 557834 | |
| MSLN | APC | R&D systems, FAB32652A | |
| CellTrace™ | Violet | InvitrogenTM, C34571 | |
| DNA | 7AAD | BD Pharmingen™, 51–68981E | |
| Fratricide A & Bystander killing | EGFR (Cetuximab biosimilar) | Biotin | R&D systems, FAB9577B |
| Streptavidin | PE | Biolegend®, 405204 | |
| CD3 | PE-Cy7 | BD Pharmingen™, 557851 | |
| CD4 | AF700 | BD Pharmingen™, 557922 | |
| CD8 | APC-Cy7 | BD Pharmingen™, 557834 | |
| MSLN | APC | R&D systems, FAB32652A | |
| CellTrace™ | Violet | InvitrogenTM, C34571 | |
| DNA | 7AAD | BD Pharmingen™, 51–68981E | |
| Fratricide B | EGFR (Cetuximab biosimilar) | Biotin | R&D systems, FAB9577B |
| Streptavidin | PE | Biolegend®, 405204 | |
| CD3 | PE-Cy7 | BD Pharmingen™, 557851 | |
| CD4 | AF700 | BD Pharmingen™, 557922 | |
| CD8 | APC-Cy7 | BD Pharmingen™, 557834 | |
| MSLN | APC | R&D systems, FAB32652A | |
| CD279 (PD-1) | FITC | BD Pharmingen™, 557860 | |
| CD223 (LAG-3) | BV650 | Biolegend®, 369316 | |
| CD366 (TIM-3) | BV785 | Biolegend®, 345032 | |
| CellTrace™ | Violet | InvitrogenTM, C34571 | |
| DNA | 7AAD | BD Pharmingen™, 51–68981E | |
| Spheroid infiltration | EGFR (Cetuximab biosimilar) | AF488 | R&D, FAB9577G-100 |
| CD3 | Pacific blue | BioLegend®, 300431 | |
| CD4 | PerCP-Cy5.5 | BioLegend®, 344608 | |
| CD8 | APC-Cy7 | BioLegend®, 344714 | |
| Block trogocytosis | EGFR (Cetuximab biosimilar) | Biotin | R&D systems, FAB9577B |
| Streptavidin | PE | Biolegend®, 405204 | |
| CD3 | PE-Cy7 | BD Pharmingen™, 557851 | |
| CD4 | AF700 | BD Pharmingen™, 557922 | |
| CD8 | APC-Cy7 | BioLegend®, 344714 | |
| MSLN | APC | R&D systems, FAB32652A | |
| DNA | 7AAD | BD Pharmingen™, 51–68981E |